메뉴 건너뛰기




Volumn 99, Issue 18, 2013, Pages 1305-1306

Tissue necrosis factor α and targeting its receptor in ischaemic heart disease

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; ETANERCEPT; INTERLEUKIN 6; METHYLPREDNISOLONE; PEXELIZUMAB; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA;

EID: 84882453791     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2013-303960     Document Type: Editorial
Times cited : (3)

References (13)
  • 1
    • 84874784306 scopus 로고    scopus 로고
    • Molecular circuits in thrombosis and inflammation
    • Esmon CT. Molecular circuits in thrombosis and inflammation. Thromb Haemost 2013;109: 416-20.
    • (2013) Thromb Haemost , vol.109 , pp. 416-420
    • Esmon, C.T.1
  • 2
    • 84855371090 scopus 로고    scopus 로고
    • Regulation of the inflammatory response in cardiac repair
    • Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. Circ Res 2012;110:159-73.
    • (2012) Circ Res , vol.110 , pp. 159-173
    • Frangogiannis, N.G.1
  • 3
    • 0036258785 scopus 로고    scopus 로고
    • Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells
    • Baj-Krzyworzeka M, Majka M, Pratico D, et al. Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells. Exp Hematol 2002;30:450-9.
    • (2002) Exp Hematol , vol.30 , pp. 450-459
    • Baj-Krzyworzeka, M.1    Majka, M.2    Pratico, D.3
  • 4
    • 24744432090 scopus 로고    scopus 로고
    • Tumor necrosis factor-alpha as trigger of platelet activation in patients with heart failure
    • Pignatelli P, De Biase L, Lenti L, et al. Tumor necrosis factor-alpha as trigger of platelet activation in patients with heart failure. Blood 2005;106:1992-4.
    • (2005) Blood , vol.106 , pp. 1992-1994
    • Pignatelli, P.1    De Biase, L.2    Lenti, L.3
  • 5
    • 0034625079 scopus 로고    scopus 로고
    • Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction
    • Ridker PM, Rifai N, Pfeffer M, et al. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000;101:2149-53.
    • (2000) Circulation , vol.101 , pp. 2149-2153
    • Ridker, P.M.1    Rifai, N.2    Pfeffer, M.3
  • 6
    • 84882582318 scopus 로고    scopus 로고
    • Cardiovascular effects of tumour necrosis factor alpha antagonism in patients with acute myocardial infarction: A first in human study
    • Padfield GJ, Din JN, Koushiappi E, et al. Cardiovascular effects of tumour necrosis factor alpha antagonism in patients with acute myocardial infarction: a first in human study. Heart 2013;99:1330-5.
    • (2013) Heart , vol.99 , pp. 1330-1335
    • Padfield, G.J.1    Din, J.N.2    Koushiappi, E.3
  • 7
    • 0037406233 scopus 로고    scopus 로고
    • Meta-analysis of corticosteroid treatment in acute myocardial infarction
    • Giugliano GR, Giugliano RP, Gibson CM, et al. Meta-analysis of corticosteroid treatment in acute myocardial infarction. Am J Cardiol 2003;91:1055-9.
    • (2003) Am J Cardiol , vol.91 , pp. 1055-1059
    • Giugliano, G.R.1    Giugliano, R.P.2    Gibson, C.M.3
  • 8
    • 77951665667 scopus 로고    scopus 로고
    • Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study)
    • Abbate A, Kontos MC, Grizzard JD, et al. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol 2010;105:1371-7 e1.
    • (2010) Am J Cardiol , vol.105
    • Abbate, A.1    Kontos, M.C.2    Grizzard, J.D.3
  • 9
    • 0041732120 scopus 로고    scopus 로고
    • Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: The COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial
    • Mahaffey KW, Granger CB, Nicolau JC, et al. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation 2003;108:1176-83.
    • (2003) Circulation , vol.108 , pp. 1176-1183
    • Mahaffey, K.W.1    Granger, C.B.2    Nicolau, J.C.3
  • 10
    • 0042917638 scopus 로고    scopus 로고
    • Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial
    • Granger CB, Mahaffey KW, Weaver WD, et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 2003;108:1184-90.
    • (2003) Circulation , vol.108 , pp. 1184-1190
    • Granger, C.B.1    Mahaffey, K.W.2    Weaver, W.D.3
  • 11
    • 33845981823 scopus 로고    scopus 로고
    • Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: A randomized controlled trial
    • Armstrong PW, Granger CB, Adams PX, et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA 2007;297:43-51.
    • (2007) JAMA , vol.297 , pp. 43-51
    • Armstrong, P.W.1    Granger, C.B.2    Adams, P.X.3
  • 12
    • 22544476866 scopus 로고    scopus 로고
    • Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: A substudy of the COMMA trial
    • Theroux P, Armstrong PW, Mahaffey KW, et al. Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. Eur Heart J 2005;26:1964-70.
    • (2005) Eur Heart J , vol.26 , pp. 1964-1970
    • Theroux, P.1    Armstrong, P.W.2    Mahaffey, K.W.3
  • 13
    • 11144355760 scopus 로고    scopus 로고
    • Targeted anticytokine therapy in patients with chronic heart failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)
    • Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109:1594-602.
    • (2004) Circulation , vol.109 , pp. 1594-1602
    • Mann, D.L.1    McMurray, J.J.2    Packer, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.